TRIPLE-NEGATIVE breast cancer (TNBC) remains one of the most aggressive subtypes of breast cancer, with limited targeted ...

For centuries, the European honeybee has given people honey, wax, propolis, and even venom. Now, scientists are looking ...

Antibody-drug conjugates are currently being investigated in more than 260 clinical trials.“It’s going to be the next novel ...

Gilead has cemented the role of its TROP2 drug Trodelvy in triple-negative breast cancer with a study win in combination with MSD's Keytruda.

AstraZeneca and Daiichi Sankyo have claimed FDA approval for a second antibody-drug conjugate for breast cancer, TROP2-directed Datroway.

Triple-negative breast cancer immunotherapeutic efficacy is greatly affected by oxidative imbalance within the lymph nodes, driving dendritic cell dysfunction.